SHELTON, CT / ACCESSWIRE / May 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its ...
A University of Alberta research team has uncovered a new class of drugs with the potential to prevent or treat infections in a future viral outbreak. In the paper, published this week in Nature, the ...
SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it ...
Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has ...
SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines ...
(NYSE American:NNVC, opens new tab) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot ...
Pneumagen has previously reported positive results from both Phase 1 and a clinical proof of concept Phase 2 Human Influenza Challenge study demonstrating the potential of Neumifil New preclinical ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. The virus that causes COVID-19 might be becoming resistant to antiviral ...
SHELTON, CT / ACCESS Newswire / May 11, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the c ...
Cryo-EM images show drugs bound to herpes simplex virus protein at nearly atomic detail, while optical tweezer experiments show how the drug-bound protein behaves in real time. Harvard Medical School ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results